These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861 [TBL] [Abstract][Full Text] [Related]
24. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related]
25. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. Montemurro M; Bauer S Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258 [TBL] [Abstract][Full Text] [Related]
26. Novel approaches to imatinib- and sunitinib-resistant GIST. Reichardt P Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561 [TBL] [Abstract][Full Text] [Related]
27. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Gounder MM; Maki RG Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624 [TBL] [Abstract][Full Text] [Related]